ClinicalTrials.gg
RecruitingNCT07055919Updated Jul 9, 2025

Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).

An interventional study of Structural Heart Surgery Assist System and Manual MitraClip G4 in Mitral R and Mitral Regurgitation, sponsored by Xiamen Cardiovascular Hospital, Xiamen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Xiamen Cardiovascular Hospital, Xiamen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
27th of 40
112 · median 127
Started
2025
with 8 others
No phase
36 of 57
29 open now
Primary completion
2026-03
later than 21 of 45 live
Registered
38th of 57
by date

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 27th largest by planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2025, is one of 36 with no phase, reaches primary completion later than 21 of the 45 other live ones, and was the 38th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

This trial aims to evaluate the safety and efficacy of the Structural Heart Surgery Assist System in assisting TEER for patients with moderate-to-severe or greater degenerative or functional mitral regurgitation (MR ≥3+). A prospective, multicenter, stratified randomized controlled design with non-inferiority comparison will be used. The experimental group will utilize the Structural Heart Surgery Assist System, while the control group will undergo manual TEER (e.g., MitraClip G4).

03

Conditions studied

  • Mitral R
  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, regardless of gender.
  2. Symptomatic moderate-to-severe or greater mitral regurgitation (MR ≥3+) confirmed by transthoracic and/or transesophageal echocardiography (TTE/TEE), with planned transcatheter edge-to-edge repair (TEER):

    For degenerative mitral regurgitation (DMR):

    -Deemed high-risk for surgical intervention by the heart team:STS score ≥8% for mitral valve replacement (MVR) mortality risk; ≥6% for mitral valve repair mortality risk; OR presence of ≥2 frailty indices (moderate-to-severe frailty); OR anatomical/technical barriers to surgery; OR ≥2 major organ dysfunctions unlikely to improve postoperatively; OR other high-risk factors per heart team assessment.OR patient declines surgery.

    For functional mitral regurgitation (FMR):

    • Persistent heart failure symptoms ( Class III/IVa) despite guidelines directed medical therapy (GDMT), revascularization, or cardiac resynchronization therapy (CRT) for 1-3 months.
    • ≥1 hospitalization for heart failure within the past 12 months and/or BNP >150 pg/mL or NT-proBNP >600 pg/mL.
    • (LVEF) ≥20% and ≤50%, with left ventricular end-systolic diameter (LVESD) ≤70 mm.
  3. Primary regurgitant jet is non-commissural and deemed treatable by the investigator (secondary jets, if present, must be clinically insignificant).
  4. Volunteerly provides , understands the trial objectives, and agrees to comply with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Rheumatic mitral valve disease.
  2. Uncorrected active infection.
  3. Severe calcification or thickening in the clip coaptation zone, rendering TEER anatomically unsuitable.
  4. Intracardiac mass, thrombus, or vegetation on echocardiography.
  5. Severe right heart dysfunction (e.g., lower extremity edema with elevated jugular venous pressure and hepatomegaly) or severe pulmonary hypertension (echocardiographic systolic pulmonary artery pressure >70 mmHg).
  6. Severe left heart dysfunction ( \<20%).
  7. Acute myocardial infarction (AMI) within 30 days prior to the procedure.
  8. Recent CABG, PCI, or TAVR within 30 days prior to the procedure.
  9. Planned tricuspid/aortic valve or major vascular intervention within 30 days post-procedure.
  10. Prior surgical or transcatheter mitral valve repair/replacement.
  11. Thrombosis in access vessels (e.g., femoral vein, inferior vena cava) impeding catheter advancement.
  12. Stroke/ within 30 days or severe carotid stenosis (>70% by ultrasound).
  13. Cardiomyopathies or conditions including hypertrophic, restrictive, or infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis, sarcoidosis), constrictive pericarditis, or active endocarditis.
  14. Hemodynamic instability: Systolic blood pressure \<90 mmHg without afterload-reducing agents, cardiogenic shock, requirement for intra-aortic balloon pump (IABP) or hemodynamic support.
  15. Implanted pacemaker, CRT, or ICD within 30 days prior to the procedure.
  16. End-stage heart failure (ACC/AHA Stage D), post-heart transplant, or listed for transplant.
  17. or : ntolerance to anticoagulants, antiplatelet agents, or anesthesia, allergy to mitralclip materials (nickel/titanium, cobalt, chromium, polyester), severe contrast allergy precludes intervention.
  18. Pregnant or breastfeeding.
  19. Participation in other clinical trials (drug/device) without meeting primary endpoints.
  20. Other contraindications per investigator judgment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Structural Heart Surgery Assist System-assisted TEER.

    Device: Structural Heart Surgery Assist System

  • Placebo comparator
    Manual TEER (e.g., MitraClip G4).

    Device: Manual MitraClip G4

Interventions

  • DeviceStructural Heart Surgery Assist System

    Following femoral venous access and transseptal puncture, the steerable guide catheter and transcatheter mitral valve clip system are inserted and mounted onto the Structural Heart Surgery Assist System. The surgeon manipulates the joystick and controls on the operator console, guided by real-time animations on the human-machine interface that confirm the direction and range of device motion. Under fluoroscopic (DSA) and echocardiographic guidance, the system assists in performing edge-to-edge mitral valve repair. The procedure achieves regurgitation reduction by either creating a double-orifice configuration (A2/P2 segments) or approximating the opposing leaflets at the A1/P1 or A3/P3 regions.

  • DeviceManual MitraClip G4

    Manual MitraClip G4

06

What researchers measure

Primary outcomes

  1. Surgical Success Rate

    All of the following conditions need to be met 1. Successful implantation of 1 or more mitral clips (successful delivery and release of mitral clips with echocardiographic confirmation of leaflet clamping and successful withdrawal of the transcatheter mitral clip delivery system and manoeuvrable guide catheter); 2. Transthoracic echocardiography showing a degree of mitral regurgitation ≤2+ (as evaluated by a third-party core laboratory) prior to discharge (up to 7 days). Calculation formula: Surgical success rate (%) = (number of cases achieving surgical success in each group/total number of cases in each group) × 100% for each group

    Time frame: 7days

Secondary outcomes

  1. Instrumental technique success (trial group only)

    Definition: Successful completion of transcatheter mitral valve edge-to-edge repair (TEER) using the Structural Heart Surgery Assist System without unplanned manual intervention. Unplanned Manual Intervention: Defined as conversion to manual operation during stages that the system is designed to assist (clip delivery and leaflet capture), per the Instructions for Use of the Structural Heart Surgery Assist System. Calculation formula: Instrumental technique success (%) = (number of cases achieving Instrumental technique success in trial group/total number of cases in trial group) × 100% for each group

    Time frame: Perioperative/Periprocedural

  2. Clinical Success Rate

    Criteria (all must be met): 1. No intraoperative mortality related to the procedure. 2. Successful delivery and deployment of the mitral valve clip, with retrieval of the transcatheter clip delivery system and steerable guide catheter. 3. Placement of ≥1 mitral valve clip in the anatomically correct position. 4. No unplanned surgeries or reinterventions related to the device or access site prior to discharge (within 7 days maximum). Calculation formula: Clinical Success Rate (%) = (number of cases achieving Clinical Success in each group/total number of cases in each group) × 100% for each group

    Time frame: 7days

  3. Change in Mitral Regurgitation (MR) Severity

    Assessed by comparing baseline Mitral Regurgitation (MR) Severity 7days and 30 days post-procedure. The severity of mitral regurgitation was classified as absent (0+), mild (1+), moderate (2+), moderately severe (3+), and severe (4+). Evaluation method: based on transthoracic echocardiography results.

    Time frame: 7days/30days

  4. Change in NYHA Functional Class

    Assessed by comparing baseline NYHA class to class at 30 days post-procedure.

    Time frame: 30days

  5. Mitral Clip Implantation Time

    Definition: Time from transseptal puncture initiation to successful withdrawal of the steerable guide catheter.

    Time frame: Perioperative/Periprocedural

  6. Fluoroscopy Time

    Recorded using digital subtraction angiography (DSA) and defined as the cumulative X-ray exposure time from procedure start (defined as the first of: vascular access, anesthesia induction, or transesophageal echocardiography \[TEE\] probe insertion) to successful withdrawal of the steerable guide catheter.

    Time frame: Perioperative/Periprocedural

  7. Operator Radiation Exposure

    Measured using radiation dosimeters worn by the operator, recording cumulative radiation dose from procedure start to guide catheter withdrawal

    Time frame: Perioperative/Periprocedural

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Jul 9, 2025
StartActual
Mar 22, 2025
Primary completionEst.
Mar 22, 2026
CompletionEst.
Apr 22, 2026
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07055919
Lead sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Responsible party
Yan Wang (Principal Investigator, Xiamen Cardiovascular Hospital, Xiamen University) — Principal investigator
First posted
Jul 9, 2025
Start date
Mar 22, 2025
Primary completion
Mar 22, 2026 (estimated)
Completion
Apr 22, 2026 (estimated)
Last update
Jul 9, 2025

Study contacts

Xiang Chen, Dr
Contact
seanchenx@126.com
18033997788

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion